New Opportunities of Dupilumab in Achieving Disease Control in Preschool Age Patients with Atopic Dermatitis: Clinical Case
| Autor: | Julia G. Levina, Polina A. Pyzhyanova, Vera G. Kalugina, Kamilla E. Efendieva, Elena A. Vishneva, Anna A. Alekseeva, Leyla S. Namazova-Baranova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Педиатрическая фармакология, Vol 21, Iss 4, Pp 361-368 (2024) |
| Druh dokumentu: | article |
| ISSN: | 1727-5776 2500-3089 |
| DOI: | 10.15690/pf.v21i4.2788 |
| Popis: | Background. Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases in children. It manifests during the first year of life in majority of cases. Early AD manifestation is a risk factor for the development of other atopic spectrum diseases in the future. Nowadays, the ability of the dupilumab, as a genetically engineered biologic drug (GEBD), to modify the disease course, to reduce the frequency of AD persistence and the possibility of multimorbid atopic phenotype development is widely discussed. Thus, dupilumab management in young children with early onset and severe course arouses specific interest. Clinical case description. This article demonstrates the experience of effective administration of GEBD dupilumab in 4-year old patient with severe AD and comorbid food allergies. Continuous therapy for 12 weeks allowed to recover disease’s skin manifestations. No adverse events were reported. Conclusion. Long-term continuous dupilumab administration in children aged from 6 months to 5 years has proven its efficacy and acceptable safety profile. The potential disease-modifying effect of dupilumab is especially significant for young and preschool children due to the high risk atopic multimorbidity developing during this period. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|